Home
HelpTest Code RPSA Prostate Specific Antigen, Total (Non-Screening)
Specimen and Container/Tube
Plasma
Rejection Criteria
Whole blood/unspun samples greater than 6 hours will be
rejected.
Turnaround Time
N/A
Test Includes
N/A
Specimen Type
Plasma
Preferred Volume
0.5 mL
UCMC Collection Instructions
1. Collect sample following standard collection methods
2. Within 2 hours of collection the sample must be received in
Laboratory Service Center
3. Transport room temperature (15 – 25˚C)
Test Usage
Non-screening PSA for monitoring
therapeutic response or disease
progression.
Indicated for the measurement of total PSA in conjunction with
digital rectal examination (DRE) as an
aid in the detection of
prostate cancer in men aged 50 years or older. Prostate biopsy
is
required for diagnosis of prostate cancer. The test is further
indicated for serial measurement of PSA
to aid in the management of
cancer patients.
Critical Results
N/A
Test Limitations
The measured PSA value of a
patient���s sample can vary
depending on the testing procedure used. PSA values determined
on
patient samples by different testing procedures cannot be
directly
compared with one another and could be the cause of erroneous
medical interpretations. An inflammation or trauma of the
prostate
(e.g. in cases of urinary retention or following rectal
examination, cystoscopy, coloscopy, transurethral biopsy, laser
treatment or ergometry) can lead to PSA
elevations of varying
duration and magnitude. It is known that in rare cases PSA isoforms
do exist which may be measured differently by different
PSA tests.
Findings of this kind have occasionally been reported for
PSA tests
from various manufacturers.
Coverage Information
CMS has established a national
coverage policy (NCD) for
Medicare for this test as of November 25, 2002. Please document
medical necessity.
Typically only covered when total PSA
is in the 2.6-10.0 ng/mL
range, DRE is normal and there is either
a contraindication to
biopsy or the patient has had an initial biopsy that was
negative.
Fee Code
69198
Container/Tube
Li-Heparin, Mint Green Top
Specimen Minimum Volume
0.2 mL
Day(s) Performed
24 hours, 7 days a week including holidays.
STAT DAY(S) AND TIME(S) PERFORMED
N/A
CPT
84153
Method Name
Electrochemiluminescence Immunoassay
(ECLIA)
Reference Values
<4.0 ng/mL
Reject Due To
Whole blood/unspun samples greater than 6 hours will be
rejected.
STAT Turnaround Time
N/A
Synonyms
N/A
Offsite Collection Instructions
1. Collect sample following standard collection methods
2. Within 2 hours of collection the sample must be spun and
aliquoted
3. Transport refrigerated (2 – 8˚C)
Additional Information
Non-screening PSA for monitoring
therapeutic response or disease
progression.
There is no high-dose hook effect at Total PSA concentrations up
to 17,000 ng/mL.
Included in Additional codes
PSAB
Stability: Room Temp
n/a
Stability: Refrigerated
5 days
Stability: Frozen
6 months
Pediatric Volume
0.2 mL
Clinical Indications
Non-screening PSA for monitoring
therapeutic response or disease
progression.
Indicated for the measurement of total PSA in conjunction with
digital rectal examination (DRE) as an
aid in the detection of
prostate cancer in men aged 50 years or older. Prostate biopsy
is
required for diagnosis of prostate cancer. The test is further
indicated for serial measurement of PSA
to aid in the management of
cancer patients.
Transport Instructions
1. Collect sample following standard collection methods
2. Within 2 hours of collection the sample must be spun and
aliquoted
3. Transport?�refrigerated?�(2 �?? 8??C)
Test Components
N/A
Specimen Stability
n/a
Methodology
Electrochemiluminescence Immunoassay
(ECLIA)
Synonyms/Key Search Words
N/A